Patents Issued in March 31, 2011
  • Publication number: 20110076245
    Abstract: Novel inverse latices comprising, as inverting agents, at least one compound of formula (I): R3—[O—CH2—CH(OH)—CH2]P—OH (I) in which R3 represents a linear or branched aliphatic radical comprising from 6 to 18 carbon atoms and p an integer greater than or equal to and less than or equal to 20; and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising them.
    Type: Application
    Filed: June 22, 2009
    Publication date: March 31, 2011
    Applicant: Societe D"exploitation De Produits Pour Les Industries Chimiques Seppic
    Inventors: Olivier Braun, Georges Da Costa, Hervé Rolland, Paul Mallo
  • Publication number: 20110076246
    Abstract: Sulfur-containing ligands and methods of their utilization for binding metals and/or main group elements and removing them from fluids, solids, gases and/or tissues are disclosed.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 31, 2011
    Inventors: Boyd E. Haley, David A. Atwood
  • Publication number: 20110076247
    Abstract: Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues.
    Type: Application
    Filed: October 29, 2010
    Publication date: March 31, 2011
    Applicant: DONG-A PHARM, CO., LTD.
    Inventors: Kyung-Soo KIM, Ji-yong Jin
  • Publication number: 20110076248
    Abstract: The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.
    Type: Application
    Filed: December 20, 2002
    Publication date: March 31, 2011
    Applicant: Myriad Genetics, Incorporated
    Inventors: Adrian Hobden, Kenton Zavitz, Scott Morham
  • Publication number: 20110076249
    Abstract: The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.
    Type: Application
    Filed: December 3, 2010
    Publication date: March 31, 2011
    Applicant: IRx Therapeutics, Inc.
    Inventors: John W. Hadden, Paul Naylor
  • Publication number: 20110076250
    Abstract: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks, implants, drug carriers that comprises at least one microfiber electrospun from a polymer mixture are provided. The dressings can have variable water vapor penetration characteristics and variable biodegradation times.
    Type: Application
    Filed: December 7, 2010
    Publication date: March 31, 2011
    Inventors: Bronislava G. Belenkaya, Vyacheslav N. Polevov, Valentina I. Sakharova, Claudia Polevov
  • Publication number: 20110076251
    Abstract: This invention relates to the treatment of hepatitis infections or hepatitis diseases, in particular hepatitis C. The invention more particularly relates to the use of an inhibitor and/or repressor of a nucleic acid molecule, especially gene, which is related to the proliferation and/or replication of hepatitis viruses, in particular hepatitis C viruses, in order to produce a medicament for preventing and/or curing hepatitis, in particular hepatitis C, as well as a pharmaceutical composition, preferably for preventing or treating hepatitis C diseases, said composition containing the repressor and/or inhibitor.
    Type: Application
    Filed: March 12, 2009
    Publication date: March 31, 2011
    Inventor: Joerg Friedrich Schlaak
  • Publication number: 20110076252
    Abstract: The invention relates to the use of a L-theanine for the treatment of gastroesophageal reflux disease (e.g., heart-burn) in a human or animal, including useful methods and compositions.
    Type: Application
    Filed: March 20, 2009
    Publication date: March 31, 2011
    Inventors: Burt Shulman, Barrie R. Froseth, Ravindranath S. Menon
  • Publication number: 20110076253
    Abstract: The present invention relates to compositions and methods for culturing stem cells, particularly embryonic stem cells. Specifically, the invention relates to a culture medium that supports proliferation of substantially undifferentiated stem cells, while maintaining potency of the cells. An an embodiment, the culture medium is defined and supports proliferation of substantially undifferentiated embryonic stem cells in essentially serum free and feeder cell free conditions. Compositions for making the medium and methods using the culture medium are also provided.
    Type: Application
    Filed: July 28, 2006
    Publication date: March 31, 2011
    Inventors: Michael P. Snyder, Joyce J. Lu
  • Publication number: 20110076254
    Abstract: A method for expanding a population of stem cells using a porous scaffold, a porous scaffold populated with renewed stem cells, methods of administering stem cells using the porous scaffold and cells collected from the porous scaffold, and methods for tissue engineering and treating a condition treatable by administration of stem cells using the porous scaffold and cells collected from the porous scaffold.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 31, 2011
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Miqin Zhang, Zhensheng Li, Matthew Chi-hang Leung
  • Publication number: 20110076255
    Abstract: The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury—due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.
    Type: Application
    Filed: October 22, 2010
    Publication date: March 31, 2011
    Inventors: Andrew L. Pecora, Robert A. Preti
  • Publication number: 20110076256
    Abstract: The present invention relates to a human neural stern cell, and to a pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same. More particularly, the present invention relates to a human telencephalon-derived human neural stem cell effective in the treatment of nervous system disorders and injuries, and to a pharmaceutical composition for the treatment of nervous system disorders and injuries using same, to the use of the human neural stem cell for preparing therapeutic agents for the treatment of nervous system disorders and injuries, and to a method for treating nervous system disorders and injuries, capable of administrating an effective amount of the human neural stem cells into individuals that need the human neural stem cells.
    Type: Application
    Filed: August 12, 2009
    Publication date: March 31, 2011
    Applicant: Industry-Academic Cooperation Foundation, Yonsei University
    Inventor: Kook In Park
  • Publication number: 20110076257
    Abstract: An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 31, 2011
    Inventors: Revati J. Tatake, Margaret M. O'neill, Kelli-Ann Monaco
  • Publication number: 20110076258
    Abstract: The present invention provides methods and compositions for modulating at least one T cell-dependent immune response using an inhibitor of ATP-mediated T cell activation, such as oxidized ATP, for therapeutic and research purposes.
    Type: Application
    Filed: March 3, 2009
    Publication date: March 31, 2011
    Applicant: Converge Biotech Inc.
    Inventors: Fabio Grassi, Ursula Schenk, Camillo Ricordi
  • Publication number: 20110076259
    Abstract: A method of detecting a risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the pregnant female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, comprises detecting the level of a VEGFxxxb in a sample from the pregnant female mammal at less than about 24 weeks of gestation and comparing the detected level with a reference level. A reduced level in the sample from the pregnant female mammal is indicative of a risk of the pregnant female mammal developing pre-eclampsia or a complication linked thereto or of the fetus developing the fetal or neonatal deficiency linked to maternal pre-eclampsia.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Inventors: David Owen Bates, Victoria Louise Bills, Steven James Harper, Yan Qiu
  • Publication number: 20110076260
    Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.
    Type: Application
    Filed: June 22, 2010
    Publication date: March 31, 2011
    Inventors: David A Estell, Fiona A. Harding
  • Publication number: 20110076261
    Abstract: A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent having a pH?pKa value of 0.5 or more formulated into shampoos, creams, lotions, gels, sprays, foams, pads, films, patches, and solutions for treatment of skin disorders and diseases in both humans and animals.
    Type: Application
    Filed: December 10, 2010
    Publication date: March 31, 2011
    Inventors: Bhiku Patel, Craig Woodward, Philip Gordon
  • Publication number: 20110076262
    Abstract: The present invention concerns antagonists of the FGF19/FGFR4 pathways, and the uses of same.
    Type: Application
    Filed: August 1, 2008
    Publication date: March 31, 2011
    Inventors: Mark Dennis, Luc Desnoyers, Dorothy French
  • Publication number: 20110076263
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: March 31, 2010
    Publication date: March 31, 2011
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Publication number: 20110076264
    Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 31, 2011
    Inventors: Robert Jordan, David Knight, Randall Brezski
  • Publication number: 20110076265
    Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 31, 2011
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20110076266
    Abstract: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
    Type: Application
    Filed: August 7, 2008
    Publication date: March 31, 2011
    Inventor: Juan Eduardo María Gallo Barraco
  • Publication number: 20110076267
    Abstract: Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.
    Type: Application
    Filed: April 16, 2010
    Publication date: March 31, 2011
    Inventors: Roger A. SABBADINI, William A. GARLAND, Genevieve HANSEN, Steven Tarran JONES, David Gareth WILLIAMS
  • Publication number: 20110076268
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 31, 2011
    Inventors: ROBERT ANTHONY WILLIAMSON, JEHANGIR WADIA, GABRIEL PASCUAL, ELISSA KEOGH
  • Publication number: 20110076269
    Abstract: Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and/or prevention of injuries, diseases, or conditions associated with insufficient neuronal differentiation and/or with elevated LPA levels in neural tissues.
    Type: Application
    Filed: June 23, 2010
    Publication date: March 31, 2011
    Inventors: Alice Marie Pébay, Ann Maree Turnley
  • Publication number: 20110076270
    Abstract: A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1?, CDR2? and CDR3?, CDR1? having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2? having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3? having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.
    Type: Application
    Filed: June 30, 2010
    Publication date: March 31, 2011
    Inventors: Gregorio AVERSA, Frank KOLBINGER, José M. CARBALLIDO HERRERA, Andreás ASZÓDI, José W. SALDANHA, Bruce M. HALL
  • Publication number: 20110076271
    Abstract: Disclosed herein are methods and compositions useful for the diagnosis and treatment of angiogenic disorders, including, e.g., cancer.
    Type: Application
    Filed: July 12, 2010
    Publication date: March 31, 2011
    Applicant: Genentech, Inc.
    Inventors: Maike Schmidt, Laura Sanders, Rajiv Raja, Rajesh D. Patel
  • Publication number: 20110076272
    Abstract: Disclosed herein are methods for modulating the environment of a tumor, by inhibiting the activity of the extracellular enzyme lysyl oxidase-like 2 (LOXL2). The methods disclosed herein are effective in reducing tumor growth, reducing recruitment of cells to the tumor, reducing fibroblast activation, reducing desmoplasia, reducing vasculogenesis, reducing the number of TAFs, reducing growth factor production, inhibiting collagen deposition, and increasing necrosis and pyknosis in the tumor. Exemplary inhibitors of LOXL2 activity are antibodies and siRNAs.
    Type: Application
    Filed: August 20, 2010
    Publication date: March 31, 2011
    Inventors: Victoria Smith, Peter Van Vlasselaer
  • Publication number: 20110076273
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 31, 2011
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20110076274
    Abstract: The present inventors demonstrate that the G-protein coupled receptor 55 (GPR55) is highly expressed in human aggressive breast cancer cells, and that the expression level may be correlated with the invasiveness and metastatic potential of these cells (for example metastasis to bone). In various aspects of the invention there are disclosed diagnostic tools or biomarkers that relate to the metastatic profile of breast cancer tumours. The invention also relates to pharmacological agents targeting this receptor for the purposes of inhibiting progression and spread of breast cancer.
    Type: Application
    Filed: May 13, 2009
    Publication date: March 31, 2011
    Inventors: Ruth Alexandra Ross, Michael John Rogers, Lesley Ann Ford, Anke Jozefien Roelofs
  • Publication number: 20110076275
    Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
    Type: Application
    Filed: September 26, 2008
    Publication date: March 31, 2011
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Taichi Kuramochi
  • Publication number: 20110076276
    Abstract: The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
    Type: Application
    Filed: June 26, 2008
    Publication date: March 31, 2011
    Applicants: Gilead Sciences, Inc., Korean Research Institute of Chemical Technology
    Inventors: Hongyan Guo, Choung U. Kim, Ill Y. Lee, Michael L. Mitchell, Gerry Rhodes, Jong C. Son, Lianhong Xu
  • Publication number: 20110076277
    Abstract: A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc?RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 31, 2011
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Robert Anthony
  • Publication number: 20110076278
    Abstract: Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor-1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.
    Type: Application
    Filed: August 1, 2006
    Publication date: March 31, 2011
    Inventor: Mehran Khodadoust
  • Publication number: 20110076279
    Abstract: Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Application
    Filed: October 22, 2007
    Publication date: March 31, 2011
    Applicants: SCHERING CORPORATION, XOMA TECHNOLOGY LTD.
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang
  • Publication number: 20110076280
    Abstract: Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.
    Type: Application
    Filed: August 21, 2008
    Publication date: March 31, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventor: Yusuke Nakamura
  • Publication number: 20110076281
    Abstract: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.
    Type: Application
    Filed: December 9, 2010
    Publication date: March 31, 2011
    Applicant: GENERA ISTRAZIVANJA d.o.o
    Inventors: Slobodan Vukicevic, Lovorka Grgurevic, Boris Macek
  • Publication number: 20110076282
    Abstract: A method of killing a cell having a mutation in an Adenomatous polyposis coli (APC) gene is disclosed. The method comprises contacting the cell with an inhibitor of Casein kinase I (CKI), the CKI being selected from the group consisting of CKI-alpha and CKI-delta and CKI-epsilon, thereby killing the cell. The method may be used for treating cancers. Pharmaceutical compositions for treatment of cancers are also disclosed.
    Type: Application
    Filed: May 26, 2009
    Publication date: March 31, 2011
    Applicant: Yissum Research Development Company of the Hebrew Univeristy of Jerusalem Ltd
    Inventors: Yinon Ben-Neriah, Ela Elyada, Ariel Pribluda
  • Publication number: 20110076283
    Abstract: The present invention relates to a method for predicting or diagnosing outcome of concomitant chemo-radiotherapy of a subject suffering from brain tumor. The present invention further relates to compositions and methods for treatment or prevention of tumor resistance in a subject suffering from a brain tumor and to a kit useful for predicting or diagnosing the tumor resistance in a subject treated with concomitant chemo-radiotherapy.
    Type: Application
    Filed: January 23, 2009
    Publication date: March 31, 2011
    Applicant: Universite De Lausanne
    Inventors: Monika Hegi, Anastasia Murat, Eugenia Migliavacca, Roger Stupp
  • Publication number: 20110076284
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: John Corbin, Mark L. White, Susan R. Watson, Vinay Bhaskar
  • Publication number: 20110076285
    Abstract: Disclosed herein are methods and compositions for treatment of ocular fibrosis, as occurs, for example, during the treatment of glaucoma by trabeculectomy. Compositions comprise modulators of the activity of one or more lysyl oxidase-type enzymes (e.g., LOX, LOXL2), and the methods include methods for making the modulators and methods for administration of the modulators to a subject in need thereof.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 31, 2011
    Inventors: Ingeborg Stalmans, Tine Van Bergen, Victoria Smith
  • Publication number: 20110076286
    Abstract: The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.
    Type: Application
    Filed: June 1, 2010
    Publication date: March 31, 2011
    Applicant: Curis, Inc.
    Inventors: Henryk Dudek, Irina Karavanov, Carmen Pepicelli
  • Publication number: 20110076287
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: January 16, 2009
    Publication date: March 31, 2011
    Inventors: Robert L Cohen, Edward HyungSuk Ha, Mark E. Reynolds
  • Publication number: 20110076288
    Abstract: Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, CT788, which induces T-cell activation during a Chlamydia infection.
    Type: Application
    Filed: February 21, 2007
    Publication date: March 31, 2011
    Applicant: President and Fellows of Harvard College
    Inventors: Darren E. Higgins, Michael N. Starnbach, Todd Gierahn, Nadia R. Roan
  • Publication number: 20110076289
    Abstract: The present invention provides a transgenic animal model of Alzheimer's Disease designated TgCRND8 as well as a method for making such model, which allows for the characterization of the etiology of the disease as well as for provide a system for the development and testing of potential treatments.
    Type: Application
    Filed: June 30, 2010
    Publication date: March 31, 2011
    Applicant: Governing Council of the University of Toronto
    Inventors: Peter H. St. George-Hyslop, Paul E. Fraser, David Westaway
  • Publication number: 20110076290
    Abstract: A vaccine containing AAH-loaded mature dendritic cells for treatment of AAH-expressing tumors in mammalian subjects. A method of producing primed dendritic cells is carried out by contacting isolated dendritic cells with an antigen such as AAH. Following the antigen-contacting step, the dendritic cells are contacted with a combination of cytokines such as GM-CSF and IFN-?.
    Type: Application
    Filed: July 23, 2010
    Publication date: March 31, 2011
    Inventors: Masafumi Shimoda, Jack R. Wands
  • Publication number: 20110076291
    Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 27, 2010
    Publication date: March 31, 2011
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei
  • Publication number: 20110076292
    Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: September 27, 2010
    Publication date: March 31, 2011
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
  • Publication number: 20110076293
    Abstract: Variously substituted carbonate and carbamate derivatives of triptolide compounds have good aqueous solubility and convert to biologically active compounds in vivo, at a rate which can be modulated by varying the substitution on the prodrug. The prodrugs are useful as immunosuppressive, anti-inflammatory and anticancer agents.
    Type: Application
    Filed: December 6, 2010
    Publication date: March 31, 2011
    Inventors: Dongcheng Dai, John H. Musser, Edwin S. Lennox
  • Publication number: 20110076294
    Abstract: The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use.
    Type: Application
    Filed: December 7, 2010
    Publication date: March 31, 2011
    Applicant: Aastrom Biosciences, Inc.
    Inventors: Brian Hampson, Kristin Goltry, Doug Smith, Jonathan A. Rowley, Naia Venturi